Acorda Therapeutics (NASDAQ: ACOR)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued to clients and investors on Tuesday, Stock Ratings Network reports. They currently have a $36.00 price target on the stock. Zacks‘ price objective suggests a potential upside of 3.72% from the company’s current price.
Zacks‘ analyst wrote, “Acorda reported first quarter 2013 loss of $0.03 per share, which compared unfavorably with the Zacks Consensus Estimate of earnings of $0.18 and the year-ago earnings of $0.26 per share. Ampyra sales came in at $62.3 million, reflecting an increase of 8.5%. However, Ampyra revenues decreased 14.3% on a sequential basis. Revenues were affected by seasonal factors. The company continues to expect Ampyra sales in the range of $285 – $315 million in 2013. We remain concerned about the company’s dependence on Ampyra for growth. Acorda’s pipeline, while interesting, is early-stage in nature except for diazepam nasal spray (NDA submission expected in 2013). We prefer to remain on the sidelines until we see sustained improvement in Ampyra sales. “
A number of other analysts have also recently weighed in on ACOR. Analysts at MKM Partners downgraded shares of Acorda Therapeutics from a “neutral” rating to a “sell” rating in a research note to investors on Thursday, May 2nd. Separately, analysts at RBC Capital raised their price target on shares of Acorda Therapeutics from $38.00 to $42.00 in a research note to investors on Tuesday, April 16th.
One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $37.75.
Shares of Acorda Therapeutics (NASDAQ: ACOR) traded up 0.23% during mid-day trading on Tuesday, hitting $34.79. Acorda Therapeutics has a 52 week low of $21.04 and a 52 week high of $40.87. The stock’s 50-day moving average is currently $32.59. The company has a market cap of $1.387 billion and a P/E ratio of 9.55.
Acorda Therapeutics (NASDAQ: ACOR) last released its earnings data on Thursday, May 2nd. The company reported $0.09 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.20 by $0.11. The company had revenue of $71.90 million for the quarter, compared to the consensus estimate of $80.77 million. During the same quarter in the prior year, the company posted $0.36 earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. Analysts expect that Acorda Therapeutics will post $0.27 EPS for the current fiscal year.
Acorda Therapeutics, Inc (NASDAQ: ACOR) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system.
To view Zacks’ full report, visit www.zacks.com